Mallinckrodt plc's terlipressin for hepatorenal syndrome, a life-threatening condition involving acute kidney failure in people with cirrhosis, has had a difficult path at the US Food And Drug Administration and may face more hurdles as it goes before an advisory committee.
Following a complete response letter in 2009, the sponsor had to conduct two additional clinical trials. The agency has questions...





